Genmab A/S (GMAB)
NASDAQ·Healthcare·Biotechnology
$25.10
-0.57%
Mkt Cap $16.79B
Analyst Ratings
No recent rating data.
Price Target (18 analysts)
$40.50
Range $34.00 – $48.00
Implied Upside
+61.4%
Consensus $40.50 vs current $25.10
NASDAQ·Healthcare·Biotechnology
$25.10
-0.57%
Mkt Cap $16.79B
No recent rating data.
Price Target (18 analysts)
$40.50
Range $34.00 – $48.00
+61.4%
Consensus $40.50 vs current $25.10